| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CACNa1E |
| Uniprot No | Q15878 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | 261 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CACNA1E(Cav2.3钙通道)重组蛋白的3篇参考文献概览：
1. **文献名称**：*"Structure and function of the CaV2.3 calcium channel"*
**作者**：Wang Y. et al.
**摘要**：通过冷冻电镜解析了重组人源CaV2.3(CACNA1E编码)通道的3.0 Å结构，揭示了其α1亚基的电压敏感域与钙离子选择性滤过机制，为理解其电生理特性提供结构基础。
2. **文献名称**：*"Electrophysiological characterization of recombinant CaV2.3 channels in HEK293 cells"*
**作者**：Schneider T. & Klocker N.
**摘要**：在HEK293细胞中异源表达CACNA1E重组蛋白，发现该通道在低电压下激活，并介导神经元R型钙电流，其失活特性受β辅助亚基调控。
3. **文献名称**：*"CACNA1E mutations alter synaptic plasticity and contribute to epilepsy pathogenesis"*
**作者**：Liao X. et al.
**摘要**：研究CACNA1E重组蛋白在神经元中的功能，发现其突变体导致钙内流异常，引发突触传递过度兴奋，与早发性癫痫和神经发育障碍相关。
(注：以上为模拟文献，实际研究需根据具体数据库检索。)
CACNA1E is a gene that encodes the α1E subunit of voltage-gated calcium channels (VGCCs), forming the pore of the Cav2.3 channel. These channels mediate R-type calcium currents, which play critical roles in regulating neuronal excitability, neurotransmitter release, and calcium-dependent signaling. The Cav2.3 channel is predominantly expressed in the central nervous system, pancreatic islets, and neuroendocrine cells, where it contributes to action potential shaping, hormone secretion, and synaptic plasticity. Structurally, the α1E subunit consists of four homologous domains (I-IV), each containing six transmembrane segments (S1-S6), with the S4 segment acting as a voltage sensor.
CACNA1E has garnered attention due to its association with neurological and neuropsychiatric disorders. Pathogenic variants in CACNA1E are linked to developmental and epileptic encephalopathies (DEEs), autism spectrum disorders, and chronic pain syndromes. Functional studies using recombinant CACNA1E proteins enable researchers to characterize channel properties, such as activation/inactivation kinetics, ion selectivity, and pharmacological responses. Recombinant expression systems (e.g., HEK293 cells, Xenopus oocytes) are widely employed to study disease-causing mutations, screen potential therapeutics, or investigate channel modulation by auxiliary subunits (e.g., β, α2δ).
Producing functional CACNA1E recombinant proteins remains challenging due to the channel’s large size (~250 kDa) and complex post-translational modifications. Advances in gene delivery systems, cryo-EM, and electrophysiological techniques (patch-clamp) have enhanced structural and functional insights. Research on Cav2.3 also explores its dual role as a therapeutic target: inhibition may alleviate epilepsy or neuropathic pain, while selective activation could modulate insulin secretion in diabetes. However, its widespread tissue expression necessitates caution in drug development to avoid off-target effects. Overall, CACNA1E recombinant proteins serve as vital tools for unraveling calcium channel biology and pathomechanisms.
×
